Delcath Systems (NASDAQ:DCTH) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Delcath Systems (NASDAQ:DCTH) from a buy rating to a hold rating in a report released on Sunday.

DCTH has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Delcath Systems in a research note on Wednesday, October 8th. Stephens reissued an “overweight” rating and set a $25.00 price objective on shares of Delcath Systems in a research note on Monday, June 23rd. Finally, HC Wainwright boosted their price objective on shares of Delcath Systems from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH opened at $11.37 on Friday. The firm has a fifty day moving average price of $10.92 and a two-hundred day moving average price of $12.42. The company has a market cap of $397.72 million, a price-to-earnings ratio of 227.40 and a beta of 0.84. Delcath Systems has a one year low of $8.77 and a one year high of $18.23.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.05. The firm had revenue of $24.16 million for the quarter, compared to analysts’ expectations of $22.84 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. Equities research analysts expect that Delcath Systems will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. USA Financial Formulas purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $25,000. California State Teachers Retirement System purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $26,000. Tower Research Capital LLC TRC purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $40,000. Ameritas Investment Partners Inc. purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $42,000. Finally, Legal & General Group Plc purchased a new position in shares of Delcath Systems during the second quarter valued at approximately $46,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.